Bruker Expands Noetik Collaboration to Scale AI-Driven Tissue Models
Event summary
- Bruker Spatial Biology expands collaboration with Noetik to advance tissue foundational models for therapeutic applications.
- Noetik will image thousands of additional patient samples using Bruker’s CosMx SMI platform.
- Noetik’s AI models, including the Oncology Counterfactual Therapeutics Oracle, simulate patient biology for drug discovery.
- Bruker will showcase advancements at AGBT 2026, including CosMx SMI innovations.
The big picture
Bruker’s expanded collaboration with Noetik underscores the growing intersection of AI and spatial biology in drug discovery. The partnership aims to leverage high-resolution patient data to train advanced AI models, potentially redefining therapeutic development. This aligns with broader industry trends toward precision medicine and AI-driven biotech innovation.
What we're watching
- AI Model Scaling
- The pace at which Noetik can ingest and process high-resolution CosMx data to improve model accuracy.
- Therapeutic Applications
- How Noetik’s AI models will translate into actionable drug discovery and clinical outcomes.
- Market Differentiation
- Whether Bruker’s spatial biology portfolio can maintain competitive edge in the evolving biotech landscape.
Related topics